BCRX
NASDAQ · Biotechnology
Biocryst Pharmaceuticals Inc
$9.70
-0.11 (-1.12%)
Financial Highlights (FY 2026)
Revenue
544.51M
Net Income
-107,374,547
Gross Margin
97.2%
Profit Margin
-19.7%
Rev Growth
+42.1%
D/E Ratio
2.09
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 97.2% | 97.2% | 44.3% | 44.3% |
| Operating Margin | -0.6% | -0.5% | -20.4% | -18.7% |
| Profit Margin | -19.7% | -18.7% | -17.3% | -18.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 544.51M | 383.30M | 328.14M | 317.43M |
| Gross Profit | 529.43M | 372.68M | 145.32M | 140.58M |
| Operating Income | -3,049,277 | -1,931,824 | -67,015,157 | -59,369,563 |
| Net Income | -107,374,547 | -68,025,547 | -56,674,354 | -58,578,347 |
| Gross Margin | 97.2% | 97.2% | 44.3% | 44.3% |
| Operating Margin | -0.6% | -0.5% | -20.4% | -18.7% |
| Profit Margin | -19.7% | -18.7% | -17.3% | -18.5% |
| Rev Growth | +42.1% | +42.1% | +7.1% | +23.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 627.08M | 627.08M | 92.91M | 118.94M |
| Total Equity | 300.59M | 300.59M | 596.71M | 574.48M |
| D/E Ratio | 2.09 | 2.09 | 0.16 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,573,161 | -1,052,022 | -75,730,538 | -85,752,478 |
| Free Cash Flow | — | — | -52,199,092 | -47,303,254 |